on May 5, 2005
Published online before print May 5, 2005, doi: 10.1161/01.STR.0000165923.02318.22
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 14, 2005
From the Departments of Neurology (C.B.W., R.L.S.), Biostatistics (M.C.P), Radiology and Biomedical Engineering (T.R.B.), and the Sergievsky Center (R.L.S.), Columbia University College of Physicians and Surgeons and the Mailman School of Public Health, New York, NY; the Department of Medicine (S.P.S., R.H.A.), School of Medicine, University of Colorado, Denver, Colo; and the Department of Neurology and Center for Neuroscience (C.D.), University of California-Davis, Sacramento, Calif. * To whom correspondence should be addressed. E-mail: cbw7{at}columbia.edu.
Background--Total homocysteine (tHcy) has been implicated as a risk factor for stroke and dementia, but the mechanism is unclear. White matter hyperintensities may be a risk factor for both, but studies of the relationship between tHcy and quantitative measures of white matter hyperintensity volume (WMHV) are lacking, especially in minority populations. Methods--A community-based sample of 259 subjects with baseline tHcy levels underwent pixel-based quantitative measurement of WMHV. We examined the relationship between tHcy and WMHV adjusting for age, sociodemographics, vascular risk factors, and B12 deficiency. Results--Higher levels of tHcy were associated with WMHV adjusting for sociodemographics and vascular risk factors. Conclusions--These cross-sectional data provide evidence that tHcy is a risk factor for white matter damage.
Revised on February 11, 2005
Accepted on February 14, 2005
Total Homocysteine Is Associated With White Matter Hyperintensity Volume. The Northern Manhattan Study
Clinton B. Wright MD, MS*;
Key words: homocysteine • magnetic resonance imaging • white matter
This article has been cited by other articles:
 |
|
 |
|
  P. S. Aisen, L. S. Schneider, M. Sano, R. Diaz-Arrastia, C. H. van Dyck, M. F. Weiner, T. Bottiglieri, S. Jin, K. T. Stokes, R. G. Thomas, et al. High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Controlled Trial JAMA, October 15, 2008; 300(15): 1774 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Seshadri, P. A. Wolf, A. S. Beiser, J. Selhub, R. Au, P. F. Jacques, M. Yoshita, I. H. Rosenberg, R. B. D'Agostino, and C. DeCarli Association of Plasma Total Homocysteine Levels With Subclinical Brain Injury: Cerebral Volumes, White Matter Hyperintensity, and Silent Brain Infarcts at Volumetric Magnetic Resonance Imaging in the Framingham Offspring Study Arch Neurol, May 1, 2008; 65(5): 642 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Khatri, C. B. Wright, T. L. Nickolas, M. Yoshita, M. C. Paik, G. Kranwinkel, R. L. Sacco, and C. DeCarli Chronic Kidney Disease Is Associated With White Matter Hyperintensity Volume: The Northern Manhattan Study (NOMAS) Stroke, December 1, 2007; 38(12): 3121 - 3126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Obeid, M. Kasoha, J.-P. Knapp, P. Kostopoulos, G. Becker, K. Fassbender, and W. Herrmann Folate and Methylation Status in Relation to Phosphorylated Tau Protein(181P) and {beta}-Amyloid(1-42) in Cerebrospinal Fluid Clin. Chem., June 1, 2007; 53(6): 1129 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Sacco The 2006 William Feinberg Lecture: Shifting the Paradigm From Stroke to Global Vascular Risk Estimation Stroke, June 1, 2007; 38(6): 1980 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Soumare, A. Elbaz, V. Ducros, B. Tavernier, A. Alperovitch, and C. Tzourio Cross-sectional association between homocysteine and motor function in the elderly. Neurology, September 26, 2006; 67(6): 985 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.T. Longstreth Jr Brain Vascular Disease Overt and Covert Stroke, October 1, 2005; 36(10): 2062 - 2063. [Full Text] [PDF]
|
|